Clinical Trials on Occasional Diarrhea in Ireland

Total 28 results

Intercell USA, Inc.

Completed

Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study

Traveler's Diarrhea

India, United Kingdom, Germany
Intercell USA, Inc.

Completed

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study

Travelers' Diarrhea

United Kingdom, Germany, Guatemala, Mexico
Ashley Downs Bioscience

Unknown

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

Nausea | Vomiting | Diarrhea | Oral Mucositis

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Allergan

Completed

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Irritable Bowel Syndrome With Diarrhea

United States, Canada
Tioga Pharmaceuticals
RTI Health Solutions

Completed

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Sandoz

Completed

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

HIV Infections | Diarrhea

United States
Sandoz

Completed

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

HIV Infections | Diarrhea

United States
Bausch Health Americas, Inc.

Completed

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3)

Irritable Bowel Syndrome With Diarrhea

United States, United Kingdom, Germany
Bausch Health Americas, Inc.

Completed

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea | Clostridium Infections

United States
Ironwood Pharmaceuticals, Inc.
Allergan Sales, LLC

Completed

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea (IBS-D)

United States
Bausch Health Americas, Inc.

Completed

Diarrhea Predominant Irritable Bowel Syndrome in Females

Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Irritable Bowel Syndrome | Colonic Diseases | Diarrhea | Gastrointestinal Disease

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy

Diarrhea | Radiation Enteritis

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy

Diarrhea | Colorectal Cancer | Neutropenia

United States, Canada, Puerto Rico
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome

United States
Bausch Health Americas, Inc.

Completed

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Diarrhea | Colorectal Cancer

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Puma Biotechnology, Inc.

Completed

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Early Stage HER2+ Breast Cancer

Spain, United States, France, Australia, Germany, Austria, Canada
Genzyme, a Sanofi Company

Completed

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

Diarrhea | Clostridium Enterocolitis

Australia, Belgium, France, Spain, Germany, Portugal, Switzerland, Austria, United Kingdom, Ireland, Czech Republic, Denmark, Norway, Sweden
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, Puerto Rico, United Kingdom
GlaxoSmithKline

Completed

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, United Kingdom
GlaxoSmithKline

Completed

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Colorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation Enteritis

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States

Clinical Trials on Occasional Diarrhea in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations